Pieris Pharmaceuticals Inc PIRS:NASDAQ

Last Price$1.74NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/18/22

Today's Change-0.08(4.40%)
Bid (Size)$1.37 (1)
Ask (Size)$3.42 (5)
Day Low / High$1.72 - 1.81
Volume421.9 K

View Biotechnology IndustryPeer Comparison as of 05/18/2022


Pieris Pharmaceuticals Inc ( NASDAQ )

Price: $1.74
Change: -0.08 (4.40%)
Volume: 421.9 K
4:00PM ET 5/18/2022

INmune Bio Inc ( NASDAQ )

Price: $7.25
Change: -0.24 (3.20%)
Volume: 69.7 K
4:00PM ET 5/18/2022

Cue Biopharma Inc ( NASDAQ )

Price: $3.41
Change: -0.34 (9.07%)
Volume: 235.0 K
4:00PM ET 5/18/2022

ContraFect Corp ( NASDAQ )

Price: $3.16
Change: -0.19 (5.67%)
Volume: 104.2 K
4:00PM ET 5/18/2022

AVITA Medical Inc ( NASDAQ )

Price: $5.40
Change: -0.25 (4.42%)
Volume: 94.9 K
4:00PM ET 5/18/2022

Read more news Recent News

Pieris Doses First Patient in Phase 2 Gastric Cancer Trial of Cinrebafusp Alfa
8:54AM ET 1/14/2022 MT Newswires

Pieris Pharmaceuticals (PIRS) said Friday that the first patient has been dosed in the phase two study of its cinrebafusp alfa or PRS-343 product...

Pieris Pharmaceuticals, AstraZeneca's Asthma Drug Completes Safety Review in Part 1a of Phase 2a Trial
7:47AM ET 1/03/2022 MT Newswires

Pieris Pharmaceuticals (PIRS) said Monday that part 1a of the sponsor safety review of the company's Phase 2a study of PRS-060/AZD1402, a...

Pieris Pharmaceuticals, Servier Dose First Patient in Phase 1/2 Trial of Solid Tumor Treatment
11:04AM ET 11/08/2021 MT Newswires

Pieris Pharmaceuticals (PIRS) and Servier said Monday that the first patient has been dosed in the phase 1/2 trial of the tetravalent bispecific fusion...

-- Earnings Flash (PIRS) PIERIS PHARMACEUTICALS Posts Q3 Revenue $4.1M
7:09AM ET 11/02/2021 MT Newswires


Company Profile

Business DescriptionPieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA. View company web site for more details
Address255 State Street
Boston, Massachusetts 02109
Number of Employees107
Recent SEC Filing05/16/20224
President, Chief Executive Officer & DirectorStephen S. Yoder
Senior VP, Chief Financial & Accounting OfficerThomas Bures
Vice President-Clinical OperationsKayti Aviano
Chief Scientific Officer & Senior Vice PresidentHitto Kaufmann

Company Highlights

Price Open$1.77
Previous Close$1.74
52 Week Range$1.61 - 6.15
Market Capitalization$128.9 M
Shares Outstanding74.1 M
SectorHealth Technology
Next Earnings Announcement08/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.70
Beta vs. S&P 500N/A
Revenue$29.1 M
Net Profit Margin-148.54%
Return on Equity-97.54%

Analyst Ratings as of 12/31/2021

Consensus RecommendationConsensus Icon
Powered by Factset